Drug
Intravenous Immunoglobulins
Intravenous Immunoglobulins is a pharmaceutical drug with 6 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
6
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 4 completed trials
Completion Rate
100%(4/4)
Active Trials
1(17%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_4
1
17%
Ph phase_2
1
17%
Ph phase_3
4
67%
Phase Distribution
0
Early Stage
1
Mid Stage
5
Late Stage
Phase Distribution6 total trials
Phase 2Efficacy & side effects
1(16.7%)
Phase 3Large-scale testing
4(66.7%)
Phase 4Post-market surveillance
1(16.7%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
80.0%
4 of 5 finished
Non-Completion Rate
20.0%
1 ended early
Currently Active
1
trials recruiting
Total Trials
6
all time
Status Distribution
Active(1)
Completed(4)
Terminated(1)
Detailed Status
Completed4
Withdrawn1
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
6
Active
1
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Phase 21 (16.7%)
Phase 34 (66.7%)
Phase 41 (16.7%)
Trials by Status
withdrawn117%
recruiting117%
completed467%
Recent Activity
1 active trials
Showing 5 of 6
recruitingphase_3
IgIV Plus Prednisone vs High-dose Dexamethasone for ITP
NCT04968899
withdrawnphase_3
Intravenous Immunoglobulins in Complex-regional Pain Syndrome
NCT00949065
completedphase_3
Intravenous Immunoglobulin (IVIg) for Parvovirus B19(PVB19) Mediated Cardiomyopathy
NCT00892112
completedphase_4
Treatment of Deficient Subclass or Anti-polysaccharide Antibody Response
NCT00522821
completedphase_2
Intravenous Immunoglobulins in Severe and Refractory Solar Urticaria
NCT01360658
Clinical Trials (6)
Showing 6 of 6 trials
NCT04968899Phase 3
IgIV Plus Prednisone vs High-dose Dexamethasone for ITP
NCT00949065Phase 3
Intravenous Immunoglobulins in Complex-regional Pain Syndrome
NCT00892112Phase 3
Intravenous Immunoglobulin (IVIg) for Parvovirus B19(PVB19) Mediated Cardiomyopathy
NCT00522821Phase 4
Treatment of Deficient Subclass or Anti-polysaccharide Antibody Response
NCT01360658Phase 2
Intravenous Immunoglobulins in Severe and Refractory Solar Urticaria
NCT01537575Phase 3
Intravenous Immunoglobulins for Post-Polio Syndrome
All 6 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 6